Harbin Medisan Pharmaceutical Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Jian Fei Qin
Chief executive officer
CN¥1.6m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 11yrs |
| CEO ownership | 42.0% |
| Management average tenure | no data |
| Board average tenure | 5yrs |
Recent management updates
Recent updates
Harbin Medisan Pharmaceutical Co., Ltd.'s (SZSE:002900) Shares Climb 25% But Its Business Is Yet to Catch Up
Nov 11
Harbin Medisan Pharmaceutical (SZSE:002900) Posted Weak Earnings But There Is More To Worry About
Sep 05Harbin Medisan Pharmaceutical (SZSE:002900) Will Pay A Larger Dividend Than Last Year At CN¥0.20
Jun 01Is Harbin Medisan Pharmaceutical (SZSE:002900) A Risky Investment?
May 23Harbin Medisan Pharmaceutical Co., Ltd.'s (SZSE:002900) Price Is Right But Growth Is Lacking After Shares Rocket 27%
Mar 08CEO
Jian Fei Qin (61 yo)
11yrs
Tenure
CN¥1,644,000
Compensation
Mr. Jian Fei Qin serves as President and Chairman of Harbin Medisan Pharmaceutical Co., Ltd. and serves as its Director since December 24, 2013. Mr. Qin serves as an Executive Director of Beijing Ha San Li...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & President | 11yrs | CN¥1.64m | 42.03% CN¥ 1.3b | |
| VP, Board Secretary & Director | 11yrs | CN¥686.00k | 0.26% CN¥ 8.2m | |
| Director | 11yrs | no data | 11.88% CN¥ 371.6m | |
| Vice Chairman of the Board | 11yrs | CN¥835.00k | 8.72% CN¥ 272.7m | |
| Independent Director | 5yrs | CN¥80.00k | no data | |
| Independent Director | 5yrs | CN¥80.00k | no data | |
| Non-Independent Director | 5yrs | CN¥310.00k | no data | |
| Non-Independent Director | 2.1yrs | CN¥365.00k | 0.032% CN¥ 1.0m | |
| Independent Director | 2.8yrs | CN¥80.00k | no data | |
| Chairman of the Supervisory Board | 2.1yrs | no data | 0.011% CN¥ 336.4k | |
| Supervisor | 2.1yrs | no data | no data |
5.0yrs
Average Tenure
59yo
Average Age
Experienced Board: 002900's board of directors are considered experienced (5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 18:38 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Harbin Medisan Pharmaceutical Co., Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jiaxi Xu | Industrial Securities Co. Ltd. |